Mellado Rodríguez M, Osa Labrador A M
Servicio de Radiodiagnóstico, Complejo Hospitalario de Navarra A, Pamplona, Navarra, España.
Radiologia. 2013 Jul-Aug;55(4):305-14. doi: 10.1016/j.rx.2012.05.003. Epub 2012 Aug 28.
The currently available scientific evidence attests that mammographic screening and quality treatment have been able to reduce mortality attributable to breast cancer. Although screening is not without risks, population-based screening has clear advantages over opportunistic detection. Following the Council of the European Union's "Recommendations on cancer screening", all the regional Autonomous Communities in Spain have screening programs that, in general, follow the same guidelines. The "European guidelines for quality assurance in breast cancer screening and diagnosis" serve as a reference that provides an overview of all aspects of screening. To achieve the foreseen objectives for the reduction of the morbidity and mortality attributable to breast cancer, screening programs must fulfill the established quality criteria and guarantee that patients have access to the best treatment options.
目前可得的科学证据证明，乳腺钼靶筛查和高质量治疗已能够降低乳腺癌所致的死亡率。尽管筛查并非毫无风险，但基于人群的筛查相较于机会性检测具有明显优势。遵循欧盟理事会的“癌症筛查建议”，西班牙所有自治区均设有筛查项目，总体而言，这些项目遵循相同的指导方针。“欧洲乳腺癌筛查与诊断质量保证指南”可作为参考，概述了筛查的各个方面。为实现降低乳腺癌所致发病率和死亡率的预期目标，筛查项目必须满足既定的质量标准，并确保患者能够获得最佳治疗方案。
